阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3211人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2047965, encodeId=b642204e96575, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ONCOTARGET：三阴性乳腺癌遇强敌，三药联合成功攻克癌症, objectType=article, longId=114407, objectId=d91a11440e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d91a11440e5b, replyNumber=0, likeNumber=42, createdTime=2018-06-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d91a11440e5b, moduleTitle=ONCOTARGET：三阴性乳腺癌遇强敌，三药联合成功攻克癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d91a11440e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047967, encodeId=9440204e9672d, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Biol Open：靶向DANCR或是治疗三阴性乳腺癌的可行的治疗方法, objectType=article, longId=117110, objectId=e4e411e11042, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e411e11042, replyNumber=0, likeNumber=63, createdTime=2018-05-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e411e11042, moduleTitle=Biol Open：靶向DANCR或是治疗三阴性乳腺癌的可行的治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e411e11042)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047971, encodeId=f226204e971ce, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, objectType=article, longId=125226, objectId=585212522636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585212522636, replyNumber=0, likeNumber=72, createdTime=2018-04-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585212522636, moduleTitle=EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=585212522636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047959, encodeId=c3a4204e959d4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CANCER RES：Ⅱ/Ⅲ期三阴性乳腺癌患者顺铂，紫杉醇新辅助治疗是否应联合依维莫司, objectType=article, longId=110318, objectId=4e6911031847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6911031847, replyNumber=0, likeNumber=59, createdTime=2018-01-02, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6911031847, moduleTitle=CLIN CANCER RES：Ⅱ/Ⅲ期三阴性乳腺癌患者顺铂，紫杉醇新辅助治疗是否应联合依维莫司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6911031847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047949, encodeId=9ef4204e9491c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Lett：昆明动物所等发现冬凌草甲素衍生物可有效治疗三阴性乳腺癌, objectType=article, longId=97378, objectId=58459e378f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58459e378f3, replyNumber=0, likeNumber=99, createdTime=2017-10-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58459e378f3, moduleTitle=Cancer Lett：昆明动物所等发现冬凌草甲素衍生物可有效治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58459e378f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047953, encodeId=1dc1204e953f6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell：三阴性乳腺癌细胞可唆使正常细胞模仿病毒帮助肿瘤扩散并耐药, objectType=article, longId=106274, objectId=6f691062e495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f691062e495, replyNumber=0, likeNumber=56, createdTime=2018-01-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f691062e495, moduleTitle=Cell：三阴性乳腺癌细胞可唆使正常细胞模仿病毒帮助肿瘤扩散并耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f691062e495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047955, encodeId=a40c204e95513, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA：三阴性乳腺癌免疫浸润与何相关？, objectType=article, longId=108084, objectId=e15f1080847d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e15f1080847d, replyNumber=0, likeNumber=63, createdTime=2017-09-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e15f1080847d, moduleTitle=JAMA：三阴性乳腺癌免疫浸润与何相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e15f1080847d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047958, encodeId=c059204e958bd, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？, objectType=article, longId=108711, objectId=2c37108e1114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c37108e1114, replyNumber=0, likeNumber=70, createdTime=2018-06-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c37108e1114, moduleTitle=Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c37108e1114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047947, encodeId=4dfd204e94776, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低, objectType=article, longId=97071, objectId=262b9e07165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262b9e07165, replyNumber=0, likeNumber=58, createdTime=2017-06-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262b9e07165, moduleTitle=JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262b9e07165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047954, encodeId=8aed204e95419, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CANCER RES：三阴性乳腺癌高表达CDK7与不良预后有关，可作为治疗靶点, objectType=article, longId=106363, objectId=36b310636345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36b310636345, replyNumber=0, likeNumber=71, createdTime=2017-12-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36b310636345, moduleTitle=CANCER RES：三阴性乳腺癌高表达CDK7与不良预后有关，可作为治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36b310636345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047956, encodeId=29c0204e95680, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。, objectType=article, longId=108170, objectId=23731081e014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23731081e014, replyNumber=0, likeNumber=57, createdTime=2017-10-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23731081e014, moduleTitle=Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23731081e014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047942, encodeId=402d204e942fa, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Res：三阴性乳腺癌转移必需蛋白BRD4被发现, objectType=article, longId=82686, objectId=a23482686de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a23482686de, replyNumber=0, likeNumber=55, createdTime=2017-02-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a23482686de, moduleTitle=Cancer Res：三阴性乳腺癌转移必需蛋白BRD4被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a23482686de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047951, encodeId=ee35204e95123, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关, objectType=article, longId=105038, objectId=7f6e10503832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f6e10503832, replyNumber=0, likeNumber=65, createdTime=2018-02-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f6e10503832, moduleTitle=CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f6e10503832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047943, encodeId=7e24204e9434d, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PLoS Med：癌症基因组的延续：三阴性乳腺癌和癌症免疫疗法, objectType=article, longId=84386, objectId=21c784386c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21c784386c3, replyNumber=0, likeNumber=52, createdTime=2017-11-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21c784386c3, moduleTitle=PLoS Med：癌症基因组的延续：三阴性乳腺癌和癌症免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21c784386c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047944, encodeId=63de204e944d3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JNCI：新型疗法或有望治疗恶性三阴性乳腺癌亚型, objectType=article, longId=87021, objectId=9eca8e0210d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eca8e0210d, replyNumber=0, likeNumber=63, createdTime=2017-10-16, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eca8e0210d, moduleTitle=JNCI：新型疗法或有望治疗恶性三阴性乳腺癌亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eca8e0210d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047946, encodeId=aa58204e94652, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CHEM：在新辅助化疗过程中检测三阴性乳腺癌患者的特异性循环肿瘤DNA, objectType=article, longId=93592, objectId=483793592e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=483793592e2, replyNumber=0, likeNumber=64, createdTime=2017-09-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=483793592e2, moduleTitle=CLIN CHEM：在新辅助化疗过程中检测三阴性乳腺癌患者的特异性循环肿瘤DNA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=483793592e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047945, encodeId=3618204e94523, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？, objectType=article, longId=87775, objectId=93e38e7752a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e38e7752a, replyNumber=0, likeNumber=58, createdTime=2017-09-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e38e7752a, moduleTitle=引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e38e7752a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047941, encodeId=a2ea204e9419f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Sci Rep：催乳素或成治疗三阴性乳腺癌的新武器, objectType=article, longId=81241, objectId=dd7d8124144, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd7d8124144, replyNumber=0, likeNumber=60, createdTime=2017-04-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd7d8124144, moduleTitle=Sci Rep：催乳素或成治疗三阴性乳腺癌的新武器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd7d8124144)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047936, encodeId=94e7204e936cf, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell：CDK7可能成为三阴性乳腺癌划时代性靶点, objectType=article, longId=56621, objectId=2461566210b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2461566210b, replyNumber=0, likeNumber=61, createdTime=2016-03-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2461566210b, moduleTitle=Cell：CDK7可能成为三阴性乳腺癌划时代性靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2461566210b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047940, encodeId=fa72204e9408a, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, objectType=article, longId=72400, objectId=4e9ce240078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9ce240078, replyNumber=0, likeNumber=54, createdTime=2016-11-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9ce240078, moduleTitle=NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e9ce240078)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ONCOTARGET：三阴性乳腺癌遇强敌，三药联合成功攻克癌症

2018-06-30

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Biol Open：靶向DANCR或是治疗三阴性乳腺癌的可行的治疗方法

2018-05-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

EUR J Cancer：独立于EGFR的Elk1 / CIP2A信号介导了厄洛替尼衍生物TD52对三阴性乳腺癌细胞的凋亡诱导作用

2018-04-30

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CANCER RES：Ⅱ/Ⅲ期三阴性乳腺癌患者顺铂，紫杉醇新辅助治疗是否应联合依维莫司

2018-01-02

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Lett：昆明动物所等发现冬凌草甲素衍生物可有效治疗三阴性乳腺癌

2017-10-19

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell：三阴性乳腺癌细胞可唆使正常细胞模仿病毒帮助肿瘤扩散并耐药

2018-01-18

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA：三阴性乳腺癌免疫浸润与何相关？

2017-09-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？

2018-06-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA Surg：化疗后完全病理应答的HER2阳性及三阴性乳腺癌患者淋巴转移风险较低

2017-06-15

仁医06 (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CANCER RES：三阴性乳腺癌高表达CDK7与不良预后有关，可作为治疗靶点

2017-12-31

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet oncol：Ipatasertib联合紫杉醇对转移性三阴性乳腺癌的治疗效果。

2017-10-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Res：三阴性乳腺癌转移必需蛋白BRD4被发现

2017-02-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CANCER RES：三阴性乳腺癌铂基新辅助化疗期间肿瘤BRCA1反向突变增加且与治疗抵抗有关

2018-02-07

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PLoS Med：癌症基因组的延续：三阴性乳腺癌和癌症免疫疗法

2017-11-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JNCI：新型疗法或有望治疗恶性三阴性乳腺癌亚型

2017-10-16

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CHEM：在新辅助化疗过程中检测三阴性乳腺癌患者的特异性循环肿瘤DNA

2017-09-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

引发雌激素受体阳性或阴性乳腺癌的风险因素是否扮演着相同的角色？

2017-09-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Sci Rep：催乳素或成治疗三阴性乳腺癌的新武器

2017-04-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell：CDK7可能成为三阴性乳腺癌划时代性靶点

2016-03-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：Veliparib-卡铂治疗三阴性乳腺癌效果好

2016-11-29

科室
- - 订阅+
  - 更多科室
工具
服务